Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Summary

The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma (uHCC) participants.

Timeline

Start

2018-04-26

Primary completion

2019-01-07

Completion

2019-01-07

Outcome

Outcome not reported

Stopped (Enrollment): “Study recruitment was stopped due to difficulty in enrolling the targeted number of participants.”

Drugs

Indications